Integral Health Asset Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Integral Health Asset Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-50,000	Closed	-$4.33M	–	70
2023 Q2	$4.33M	Sell	50,000 -50,000	-50%	-$4.71M	0.54%	59
2023 Q1	$9.72M	Sell	100,000 -70,000	-41%	-$7.26M	1.96%	21
2022 Q4	$17.6M	Buy	170,000 +63,000	+59%	+$5.91M	3.69%	4
2022 Q3	$9.07M	Sell	107,000 -19,286	-15%	-$1.72M	1.76%	22
2022 Q2	$10.5M	Buy	126,286 +46,286	+58%	+$3.69M	2.15%	15
2022 Q1	$6.17M	Buy	80,000 +32,000	+67%	+$2.68M	1.61%	24
2021 Q4	$4.24M	Buy	48,000 +30,000	+167%	+$2.48M	1.17%	32
2021 Q3	$1.39M	Sell	18,000 -7,000	-28%	-$552K	0.4%	62
2021 Q2	$2.09M	Sell	25,000 -27,000	-52%	-$2.14M	0.57%	51
2021 Q1	$3.93M	Sell	52,000 -33,000	-39%	-$2.7M	1.12%	36
2020 Q4	$7.45M	Sell	85,000 -35,000	-29%	-$2.77M	2.22%	20
2020 Q3	$9.13M	Buy	120,000 +40,000	+50%	+$4.05M	2.79%	12
2020 Q2	$9.87M	Sell	80,000 -30,000	-27%	-$2.98M	2.95%	5
2020 Q1	$9.29M	Hold	110,000	–	–	4.09%	6
2019 Q4	$9.3M	Buy	+110,000	New	+$8.31M	3.62%	7

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Integral Health Asset Management's BMRN Position: Q3 2023 in Review

Integral Health Asset Management sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2023, closing a stake of 50,000 shares — an estimated $4.33M sold.

Integral Health Asset Management first reported a position in BMRN in Q4 2019 and held it in 15 quarters. The position peaked at $17.6M in Q4 2022. 519 funds tracked by Wall St. Rank hold BMRN as of Q3 2023.

Integral Health Asset Management reported no remaining BioMarin Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
Integral Health Asset Management sold 50,000 BioMarin Pharmaceuticals shares in Q3 2023, an estimated $4.33M.
Integral Health Asset Management first reported a position in BioMarin Pharmaceuticals in Q4 2019 and held it in 15 quarters.
Integral Health Asset Management's BioMarin Pharmaceuticals position peaked at $17.6M in Q4 2022.
519 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2023.

Based on Integral Health Asset Management's 13F filing for Q3 2023, filed 14 Nov 2023.